Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut AllergyThe study is evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergy First participant screened by Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University, OntarioDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary...

TOKYO and NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) announced that Apollo-managed funds (the “Apollo Funds”) completed the sale of their interest in ALTEMIRA Holdings Co., Ltd. (“ALTEMIRA” or the “Company”), a leading pan-Asian aluminum packaging company, to funds managed by MBK Partners. ALTEMIRA was established in April 2022, through the combination of the aluminum can and foil business formerly operated by Showa Denko K.K. (now named Resonac Holdings Corporation) and the aluminum can and rolled and extruded products business of Mitsubishi Materials Corporation. ALTEMIRA is one of the first successful examples of sponsor-led industry consolidation in the Japanese industrials sector, demonstrating Apollo’s ability to execute a complex carve-out and support the subsequent transition to a fully independent, standalone...

– The INDIGO study met its primary and all key secondary endpoints with statistically significant results – – Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucocorticoid-related toxicities – – A Biologics License Application (BLA) for obexelimab in IgG4-RD was submitted to the FDA in May – WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the presentation of additional positive data from the Phase 3 INDIGO trial evaluating obexelimab in Immunoglobulin G4-Related Disease...

CALGARY, Alberta, June 02, 2026 (GLOBE NEWSWIRE) — Maxim Power Corp. (“MAXIM” or the “Corporation“) (TSX: MXG) announced today the final director election results from its 2026 annual general meeting of shareholders held on June 2, 2026 (the “Meeting”). A ballot was conducted at the Meeting with respect to the election of the directors to hold office until the next annual meeting of shareholders. According to the proxies received and ballots cast, the following directors were elected at the Meeting to hold office until the next annual meeting of shareholders or until their successors are elected or appointed, unless such office is earlier vacated in accordance with the by-laws of the Corporation:Nominee # Votes For % Votes For # Votes Withheld % Votes WithheldWiley D. Auch 28,993,570 99.86 39,778 0.14M....

New York, NY, June 02, 2026 (GLOBE NEWSWIRE) — AmperCap Acquisition Company (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units, at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading on Wednesday, June 3, 2026, under the ticker symbol “APMCU.” Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial business combination. Once the securities constituting the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols “APMC” and “APMCR,” respectively. The offering is expected to close on June 4, 2026, subject to customary closing conditions. The Company has granted the...

DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference: Jefferies Global Healthcare Conference (NYC)Date: Thursday, June 4, 2026Time: 8:45 AM EDTFormat: Fireside Chat To register for the live webcast, please click here. A replay will be available in the Events & Presentations section of Fortrea’s Investor Relations website. Investors interested in one-on-one or group meetings should contact their Jefferies representatives. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical,...

MONTREAL, June 02, 2026 (GLOBE NEWSWIRE) — Stingray Group Inc. (“Stingray” or the “Corporation”) (TSX: RAY) today announced that it has received an exemption to treat Stingray’s subordinate voting shares and variable subordinate voting shares as a single class for certain purposes, including for applicable take-over bid and early warning reporting requirements under Canadian securities laws. Stingray applied for the exemption, which is effective immediately, to facilitate investment in its variable subordinate voting shares by non-Canadians. Pursuant to an application by Stingray, the securities regulatory authorities in each of the provinces and territories of Canada granted exemptive relief (the “Decision”) notably from (i) applicable take-over bid requirements, as contained under Canadian securities laws, such that those requirements...

VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to announce that shareholders voted in favour of all items of business at the Company’s 2026 Annual General Meeting (“AGM”) held on June 2, 2026 in Vancouver. A total of 161,451,593 votes were cast or represented by proxy at the AGM, representing 54.53% of the outstanding common shares as of the record date. The following is a tabulation of the votes submitted by proxy:DIRECTORS NUMBER OF SHARES PERCENTAGE OF VOTES CASTFOR WITHHELD/ ABSTAIN FOR WITHHELDRex J. McLennan 101,722,332 21,821,288 82.34% 17.66%Margaret M. Beck 120,939,225 2,604,394 97.89% 2.11%Daniel Dickson 122,723,008 820,612 99.34% 0.66%Amy Jacobsen 122,338,523 1,205,097 99.02% 0.98%Angela Johnson 121,358,501 2,185,118 98.23% 1.77%George...

ISS and Glass Lewis Recognize Medallion’s Successful Business Transformation Analysis Fails to Consider ZimCal’s Ideas And Risks of Replacing Any of the Proven Incumbents with Its Nominees Medallion Also Highlights Eric Kelly’s Alleged Financial Improprieties and History of Value Destruction NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) — Medallion Financial Corp. (NASDAQ: MFIN) (“Medallion” or the “Company”) today issued the following statement in connection with its 2026 Annual Meeting of Stockholders expressing strong disagreement with certain recommendations issued by ISS and Glass Lewis. The Company is facing its third consecutive proxy contest against ZimCal Asset Management LLC and its affiliates (collectively, “ZimCal”), a debtholder who promised in February 2024 to run a proxy contest “every year” unless the Company agreed...

Eletre X is built for drivers who refuse to compromise – delivering ultimate performance, 1,200+ km of range, and 9-minute charging in a practical hybrid SUV.1Available to order today, starting from €96,990.Supercar levels of performance in a practical SUV with a 900V architecture and up to 952 PS and 935 Nm of torque. No more range anxiety with EV-only range of up to 350 km; comprehensive range exceeding 1200 km (WLTP), without refuelling or charging. Ultra-fast charging with 70 kWh battery charging from 20–80% in just 9 minutes with 350 kW DC charger, making it one of the fastest charging electrified vehicles to come to market. Consistent performance in all driving conditions with 0-100 km/h in 3.3 seconds, and 0-100km/h acceleration in 3.5 seconds, even at 10% state of charge. Engineered with Lotus DNA and up to 120kg lighter...